pyrazines has been researched along with chlorambucil in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alexis Vigier, M; Arakelyan, N; Assouline, D; Bouabdallah, K; Caulet-Maugendre, S; Courby, S; Dartigeas, C; El Yamani, A; Fornecker, L; Gressin, R; Harousseau, JL; Houot, R; Le Gouill, S; Maisonneuve, H; Moles, MP; Mounier, C; Ojeda Uribe, M; Rodon, P; Sutton, L; Tournilhac, O | 1 |
| Davids, MS | 1 |
| Banerji, V; Byrd, JC; Corbett, G; Coutre, S; Cymbalista, F; Egyed, M; Flinn, IW; Fogliatto, LM; Follows, G; Ghia, P; Herishanu, Y; Izumi, R; Janssens, A; Jurczak, W; Kamdar, M; Karlsson, K; Munir, T; Munugalavadla, V; Pagel, JM; Patel, P; Salles, G; Sharman, JP; Skarbnik, A; Walewska, R; Walker, P; Wang, MH; Wierda, WG; Wong, S; Woyach, JA | 1 |
| Romero, D | 1 |
| Gao, A; Gao, W; Huo, D; Ran, X; Sheng, Z; Song, S; Yu, M; Zhu, H | 1 |
| Banerji, V; Byrd, JC; Corbett, G; Coutre, S; Cymbalista, F; Egyed, M; Ferrant, E; Flinn, IW; Fogliatto, LM; Follows, G; Ghia, P; Herishanu, Y; Janssens, A; Jurczak, W; Kamdar, M; Karlsson, K; Munir, T; Munugalavadla, V; Pagel, JM; Sharman, JP; Skarbnik, A; Walewska, R; Walker, P; Wang, MH; Wierda, WG; Woyach, JA; Yu, T | 1 |
1 review(s) available for pyrazines and chlorambucil
| Article | Year |
|---|---|
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Prospective Studies; Pyrazines; Sulfonamides | 2020 |
2 trial(s) available for pyrazines and chlorambucil
| Article | Year |
|---|---|
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chlorambucil; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Pyrazines; Rituximab; Treatment Outcome | 2012 |
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Progression-Free Survival; Pyrazines | 2020 |
3 other study(ies) available for pyrazines and chlorambucil
| Article | Year |
|---|---|
Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia.
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines | 2020 |
Acalabrutinib - a new option in CLL.
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines | 2020 |
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chlorambucil; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrazines | 2022 |